mrs DEBORAH WALTER

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); H.R. 3204: The Drug Quality and Security Act; CMMI Proposed Part B Payment Model; CMS Part B Demo

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); CMMI Proposed Part B Payment Model

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); H.R. 3204: The Drug Quality and Security Act; CMMI Proposed Part B Payment Model; CMS Part B Demo

H.R. 3204: The Drug Quality and Security Act

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); H.R. 3204: The Drug Quality and Security Act; CMMI Proposed Part B Payment Model; CMS Part B Demo

H.R. 3204: The Drug Quality and Security Act

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); H.R. 3204: The Drug Quality and Security Act; CMMI Proposed Part B Payment Model; CMS Part B Demo

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); H.R. 3204: The Drug Quality and Security Act; CMMI Proposed Part B Payment Model; CMS Part B Demo

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); CMMI Proposed Part B Payment Model

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); H.R. 3204: The Drug Quality and Security Act; CMMI Proposed Part B Payment Model; CMS Part B Demo

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classesprovision of Affordable Care Act (S648); TOMM-40 (HR 6); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classesprovision of Affordable Care Act (S648); TOMM-40 (HR 6); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classesprovision of Affordable Care Act (S648); TOMM-40 (HR 6); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Part D forumulary requirements-manual; Alzheimer's disease Part D coverage; CMS letter re: quarterly NOC update

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Part D forumulary requirements-manual; Alzheimer's disease Part D coverage; CMS letter re: quarterly NOC update

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classesprovision of Affordable Care Act (S648); TOMM-40 (HR 6); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2404/S 1509 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act (S648); Alzheimer's disease Part D coverage

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Medicaid entitlement reform and codifying protected classes

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Sec. 3307 of the Affordable Care Act. Improving formulary requirements for prescription drug plans and MA-PD plans with respect to certain categories or classes of drugs; Medicaid entitlement reform and codifying protected classes

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Protected classes provision of Affordable Care Act; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; Proposed Rule; Medicaid entitlement reform

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Sec. 3307 of the Affordable Care Act. Improving formulary requirements for prescription drug plans and MA-PD plans with respect to certain categories or classes of drugs; Medicaid entitlement reform and codifying protected classes

Medicare Part Dactivities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); CMS proposed rule on protected classes; H.R. 4160, the Keep the Promise to Seniors Act; Helping Families In Mental Health Crisis Act (Murphy bill); Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs Proposed Rule

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

H.R. 3204: The Drug Quality and Security Act

Medicare Part Dactivities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); CMS proposed rule on protected classes; H.R. 4160, the Keep the Promise to Seniors Act; Helping Families In Mental Health Crisis Act (Murphy bill); Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs Proposed Rule

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Sec. 3307 of the Affordable Care Act. Improving formulary requirements for prescription drug plans and MA-PD plans with respect to certain categories or classes of drugs; Medicaid entitlement reform and codifying protected classes

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Sec. 3307 of the Affordable Care Act. Improving formulary requirements for prescription drug plans and MA-PD plans with respect to certain categories or classes of drugs; Medicaid entitlement reform and codifying protected classes

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Part D Protected classes provision of Affordable Care Act; Medicaid entitlement reform and codifying protected classes

Medicare Part D-activities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); Protected classes provision of Affordable Care Act; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; Proposed Rule; Medicaid entitlement reform

Medicare Part Dactivities related to HR 2415/S 1184 (The Treat and Reduce Obesity Act of 2013); CMS proposed rule on protected classes; H.R. 4160, the Keep the Promise to Seniors Act; Helping Families In Mental Health Crisis Act (Murphy bill); Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs Proposed Rule

S 959-The Pharmaceutical Compounding Quality and Accountability Act; HR 1919-The Safeguarding America's Pharmaceuticals Act of 2013

S 959-The Pharmaceutical Compounding Quality and Accountability Act; HR 1919-The Safeguarding America's Pharmaceuticals Act of 2013

S 959-The Pharmaceutical Compounding Quality and Accountability Act; HR 1919-The Safeguarding America's Pharmaceuticals Act of 2013

S 959-The Pharmaceutical Compounding Quality and Accountability Act; HR 1919-The Safeguarding America's Pharmaceuticals Act of 2013

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, U.S. and foreign supply chain and drug shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization; labeling, Best Pharmaceuticals Research Act, Pediatric Research Equity Act, Accelerated approvals, TREAT Act

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, U.S. and foreign supply chain and drug shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization; labeling, Best Pharmaceuticals Research Act, Pediatric Research Equity Act, Accelerated approvals, TREAT Act

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions; Tax Relief and Job Creation Act of 2012 (H.R. 3630); Cong. Ryan and President Obama budget proposals

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD, value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics,

health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;

health reform and the un/underinsured and implications of ACA SCOTUS decision; chronic disease legislation (diabetes, mental health, obesity, CKD); value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; HR 5 IPAB repeal;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Safety legislation; drug pedigree, supply chain/shortage issues; Safeguarding Americas Pharmaceuticals Act; counterfiet and serialization;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap ;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;

340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing; S. 1699 Prescription Drug Cost Reduction Act; HR 3765 Temporary Payroll Tax Cut Continuation Act; HR 3765 Conflict of interest provisions

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations

General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations

H.R. 1346/S. 540 The Medical Device Safety Act

S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.

S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.

HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act

HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues

S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.

HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); S 7, Generics First Act of 2009; End Stage Renal Disease proposed rules; TRICARE, HR 3590/4872

HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act

HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D coverage gap implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease final rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization 340B expansion; PCORI

HR. 444 340B Program Improvement and Integrity Act of 2009, HR 684/S 330 The Medicare Prescription Drug Savings and Choice Act of 2009, HR 904 Medicaid Prescription Drug Rebate Equalization Act of 2009, Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); S 7, Generics First Act of 2009; End Stage Renal Disease proposed rules; TRICARE, HR 3590/4872

HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease proposed rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization

HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues

HR 759 Food and Drug Administration Globalization Act of 2009, S. 525 Pharmaceutical Market Access and Drug Safety Act of 2009 and General Importation issues, H.R. 2749 Food Safety Safety Enhancement Act, S. 882 The Drug and Device Accountability Act of 2009, Prescription Drug User Fee Act of 2012 preparation, general pedigree and chain drug supply issues, HR 4678 Foreign Manufacturers Legal Accountiblity Act

HR 4899 Supplemental Appropriations (340B-1 and AMP), Part D general issues, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform (see HCR bills); End Stage Renal Disease proposed rules; TRICARE, HR 684/S330 Medicare prescription drug price negotiation Act of 2010, HR 4872 Health Care Reconcilation Act of 2010, HR 3590 Patient Protection and Affordable Care Act, Tax Extenders bills, HR 904 Medicaid Prescription Drug Rebate Equalization